These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 8487245)

  • 1. Preclinical and clinical pharmacology of carvedilol.
    Ruffolo RR; Boyle DA; Venuti RP; Lukas MA
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S2-15. PubMed ID: 8487245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
    Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
    J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
    Abshagen U
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol.
    Bril A; Slivjak M; DiMartino MJ; Feuerstein GZ; Linee P; Poyser RH; Ruffolo RR; Smith EF
    Cardiovasc Res; 1992 May; 26(5):518-25. PubMed ID: 1359930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacology of carvedilol.
    Ruffolo RR; Gellai M; Hieble JP; Willette RN; Nichols AJ
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S82-8. PubMed ID: 1974511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure.
    Ruffolo RR; Feuerstein GZ
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():247-56. PubMed ID: 9211017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection.
    Feuerstein GZ; Ruffolo RR
    Eur Heart J; 1995 Jul; 16 Suppl F():38-42. PubMed ID: 8521883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocardial protection with carvedilol.
    Feuerstein GZ; Hamburger SA; Smith EF; Bril A; Ruffolo RR
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S138-41. PubMed ID: 1378142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection.
    Feuerstein GZ; Ruffolo RR
    Eur Heart J; 1996 Apr; 17 Suppl B():24-9. PubMed ID: 8733068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol.
    Nichols AJ; Gellai M; Ruffolo RR
    Fundam Clin Pharmacol; 1991; 5(1):25-38. PubMed ID: 1712335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    McTavish D; Campoli-Richards D; Sorkin EM
    Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Carvedilol].
    Antepohl W; Herzig S; Böhm M
    Dtsch Med Wochenschr; 1997 Jun; 122(25-26):833-4. PubMed ID: 9244672
    [No Abstract]   [Full Text] [Related]  

  • 15. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
    Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
    J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective potential of carvedilol.
    Ruffolo RR; Bril A; Feuerstein GZ
    Cardiology; 1993; 82 Suppl 3():24-8. PubMed ID: 8106160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carvedilol in the treatment of hypertension--a review of the clinical data base.
    Hansson L; Himmelmann A
    Scand Cardiovasc J Suppl; 1998; 47():67-80. PubMed ID: 9540136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
    Barone FC; Nelson AH; Ohlstein EH; Willette RN; Sealey JE; Laragh JH; Campbell WG; Feuerstein GZ
    J Pharmacol Exp Ther; 1996 Nov; 279(2):948-55. PubMed ID: 8930204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of carvedilol controlled-release in cardiovascular disease.
    Fonarow GC
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.